Our innovative processes include protocol design, site training, and real time data quality analysis

CNS drug development norms are being challenged. Nowadays Clinical Development Programs in the Central Nervous System (CNS) reach the highest failure rates across all therapeutic areas. Unsurprisingly this had led to a challenging of accepted and established norms by CNS drug developers.

You can minimise risk and maximise your probability of success through:

  • Access to the latest, applied technology innovation and processes
  • Working with our highly qualified and therapeutically trained staff
  • Real time data quality monitoring and analysis

ICON CNS experience in last five years

  • 157

    Studies

  • 42,000

    Patients

  • 5,700

    Sites worldwide
File Thumbnail

Whitepaper: Key Considerations for Trials in Chronic Pain

Download the whitepaper

Services for CNS, Pain and Ageing Diseases

Our Protocol and Clinical Development Plans service is complemented with Adaptive Design competency and regulatory approved software. Our full service study/program implementation and execution includes: 

  • Laboratory and imaging biomarker capability
  • CNS site and KOL expert network access
  • (Electronic) Clinical Outcomes Assessment and digital endpoints expertise
  • Access to biobanks and patient registries
  • Advice on use and implementation of innovative wearable technologies
File Thumbnail

Whitepaper: Key Considerations for Parkinson’s Disease Trials

Download the whitepaper

Dedicated specialist teams

All staff assigned to projects including; Project Management, Drug Development, Site Identification and Feasibility, and Medical oversight attend customised training programs. Over the past 5 years ICON have conducted phase II & III studies in a range of CNS indications. We also offer dedicated teams for rare and paediatric CNS programs.

File Thumbnail

Factsheet: Key Considerations for Epilepsy Trials

Download the factsheet